UniProt ID | VPS29_HUMAN | |
---|---|---|
UniProt AC | Q9UBQ0 | |
Protein Name | Vacuolar protein sorting-associated protein 29 | |
Gene Name | VPS29 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 182 | |
Subcellular Localization |
Cytoplasm. Membrane Peripheral membrane protein. Endosome membrane Peripheral membrane protein . Early endosome . Late endosome . |
|
Protein Description | Acts as component of the retromer cargo-selective complex (CSC). The CSC is believed to be the core functional component of retromer or respective retromer complex variants acting to prevent missorting of selected transmembrane cargo proteins into the lysosomal degradation pathway. The recruitment of the CSC to the endosomal membrane involves RAB7A and SNX3. The SNX-BAR retromer mediates retrograde transport of cargo proteins from endosomes to the trans-Golgi network (TGN) and is involved in endosome-to-plasma membrane transport for cargo protein recycling. The SNX3-retromer mediates the retrograde endosome-to-TGN transport of WLS distinct from the SNX-BAR retromer pathway. The SNX27-retromer is believed to be involved in endosome-to-plasma membrane trafficking and recycling of a broad spectrum of cargo proteins. The CSC seems to act as recruitment hub for other proteins, such as the WASH complex and TBC1D5. Required to regulate transcytosis of the polymeric immunoglobulin receptor (pIgR-pIgA) (Probable). Involved in GLUT1 endosome-to-plasma membrane trafficking; the function is dependent of association with ANKRD27. [PubMed: 24856514] | |
Protein Sequence | MLVLVLGDLHIPHRCNSLPAKFKKLLVPGKIQHILCTGNLCTKESYDYLKTLAGDVHIVRGDFDENLNYPEQKVVTVGQFKIGLIHGHQVIPWGDMASLALLQRQFDVDILISGHTHKFEAFEHENKFYINPGSATGAYNALETNIIPSFVLMDIQASTVVTYVYQLIGDDVKVERIEYKKP | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
17 | Phosphorylation | HIPHRCNSLPAKFKK CCCCCCCCCCHHHHH | 39.08 | 27251275 | |
21 | Acetylation | RCNSLPAKFKKLLVP CCCCCCHHHHHHCCC | 56.64 | 25953088 | |
21 | Ubiquitination | RCNSLPAKFKKLLVP CCCCCCHHHHHHCCC | 56.64 | - | |
24 | Malonylation | SLPAKFKKLLVPGKI CCCHHHHHHCCCCCC | 50.62 | 26320211 | |
24 | 2-Hydroxyisobutyrylation | SLPAKFKKLLVPGKI CCCHHHHHHCCCCCC | 50.62 | - | |
24 | Ubiquitination | SLPAKFKKLLVPGKI CCCHHHHHHCCCCCC | 50.62 | - | |
30 | Ubiquitination | KKLLVPGKIQHILCT HHHCCCCCCCEEEEC | 32.87 | - | |
30 | Acetylation | KKLLVPGKIQHILCT HHHCCCCCCCEEEEC | 32.87 | 25953088 | |
37 | Phosphorylation | KIQHILCTGNLCTKE CCCEEEECCCCCCHH | 26.17 | 25693802 | |
42 | Phosphorylation | LCTGNLCTKESYDYL EECCCCCCHHHHHHH | 40.80 | 25693802 | |
43 | Acetylation | CTGNLCTKESYDYLK ECCCCCCHHHHHHHH | 43.60 | 26051181 | |
43 | Ubiquitination | CTGNLCTKESYDYLK ECCCCCCHHHHHHHH | 43.60 | - | |
45 | Phosphorylation | GNLCTKESYDYLKTL CCCCCHHHHHHHHHH | 25.51 | 25693802 | |
46 | Phosphorylation | NLCTKESYDYLKTLA CCCCHHHHHHHHHHC | 15.08 | 28102081 | |
48 | Phosphorylation | CTKESYDYLKTLAGD CCHHHHHHHHHHCCC | 11.23 | 28102081 | |
50 (in isoform 1) | Ubiquitination | - | 34.95 | 21906983 | |
50 | Acetylation | KESYDYLKTLAGDVH HHHHHHHHHHCCCEE | 34.95 | 19608861 | |
50 | Ubiquitination | KESYDYLKTLAGDVH HHHHHHHHHHCCCEE | 34.95 | 21906983 | |
50 | 2-Hydroxyisobutyrylation | KESYDYLKTLAGDVH HHHHHHHHHHCCCEE | 34.95 | - | |
54 (in isoform 2) | Ubiquitination | - | 40.35 | 21906983 | |
54 | Ubiquitination | DYLKTLAGDVHIVRG HHHHHHCCCEEEEEC | 40.35 | 19608861 | |
54 | Acetylation | DYLKTLAGDVHIVRG HHHHHHCCCEEEEEC | 40.35 | 19608861 | |
69 | Phosphorylation | DFDENLNYPEQKVVT CCCCCCCCCCCEEEE | 16.00 | 28152594 | |
73 | Acetylation | NLNYPEQKVVTVGQF CCCCCCCEEEEEEEE | 36.69 | 23954790 | |
73 | Ubiquitination | NLNYPEQKVVTVGQF CCCCCCCEEEEEEEE | 36.69 | 2190698 | |
73 | Sumoylation | NLNYPEQKVVTVGQF CCCCCCCEEEEEEEE | 36.69 | - | |
73 (in isoform 1) | Ubiquitination | - | 36.69 | 21906983 | |
77 (in isoform 2) | Ubiquitination | - | 3.71 | 21906983 | |
96 | Sulfoxidation | QVIPWGDMASLALLQ EEEECHHHHHHHHHH | 2.11 | 30846556 | |
173 | Ubiquitination | QLIGDDVKVERIEYK HHHCCCCEEEEEEEC | 45.43 | - | |
173 | Sumoylation | QLIGDDVKVERIEYK HHHCCCCEEEEEEEC | 45.43 | - |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of VPS29_HUMAN !! |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of VPS29_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of VPS29_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-50, AND MASS SPECTROMETRY. |